These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 17428868)

  • 1. Successful topical respiratory tract immunization of primates against Ebola virus.
    Bukreyev A; Rollin PE; Tate MK; Yang L; Zaki SR; Shieh WJ; Murphy BR; Collins PL; Sanchez A
    J Virol; 2007 Jun; 81(12):6379-88. PubMed ID: 17428868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals.
    Yang L; Sanchez A; Ward JM; Murphy BR; Collins PL; Bukreyev A
    Virology; 2008 Aug; 377(2):255-64. PubMed ID: 18570964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.
    Bukreyev AA; Dinapoli JM; Yang L; Murphy BR; Collins PL
    Virology; 2010 Apr; 399(2):290-8. PubMed ID: 20129638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.
    DiNapoli JM; Yang L; Samal SK; Murphy BR; Collins PL; Bukreyev A
    Vaccine; 2010 Dec; 29(1):17-25. PubMed ID: 21034822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.
    Bukreyev A; Yang L; Zaki SR; Shieh WJ; Rollin PE; Murphy BR; Collins PL; Sanchez A
    J Virol; 2006 Mar; 80(5):2267-79. PubMed ID: 16474134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.
    Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
    J Virol; 2017 May; 91(10):. PubMed ID: 28250127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection.
    Choi JH; Jonsson-Schmunk K; Qiu X; Shedlock DJ; Strong J; Xu JX; Michie KL; Audet J; Fernando L; Myers MJ; Weiner D; Bajrovic I; Tran LQ; Wong G; Bello A; Kobinger GP; Schafer SC; Croyle MA
    Mol Pharm; 2015 Aug; 12(8):2712-31. PubMed ID: 25363619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.
    Meyer M; Garron T; Lubaki NM; Mire CE; Fenton KA; Klages C; Olinger GG; Geisbert TW; Collins PL; Bukreyev A
    J Clin Invest; 2015 Aug; 125(8):3241-55. PubMed ID: 26168222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
    Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
    Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.
    Pratt WD; Wang D; Nichols DK; Luo M; Woraratanadharm J; Dye JM; Holman DH; Dong JY
    Clin Vaccine Immunol; 2010 Apr; 17(4):572-81. PubMed ID: 20181765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
    Ledgerwood JE; Costner P; Desai N; Holman L; Enama ME; Yamshchikov G; Mulangu S; Hu Z; Andrews CA; Sheets RA; Koup RA; Roederer M; Bailer R; Mascola JR; Pau MG; Sullivan NJ; Goudsmit J; Nabel GJ; Graham BS;
    Vaccine; 2010 Dec; 29(2):304-13. PubMed ID: 21034824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.
    Sullivan NJ; Geisbert TW; Geisbert JB; Shedlock DJ; Xu L; Lamoreaux L; Custers JH; Popernack PM; Yang ZY; Pau MG; Roederer M; Koup RA; Goudsmit J; Jahrling PB; Nabel GJ
    PLoS Med; 2006 Jun; 3(6):e177. PubMed ID: 16683867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a preventive vaccine for Ebola virus infection in primates.
    Sullivan NJ; Sanchez A; Rollin PE; Yang ZY; Nabel GJ
    Nature; 2000 Nov; 408(6812):605-9. PubMed ID: 11117750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.
    Wong G; Richardson JS; Pillet S; Racine T; Patel A; Soule G; Ennis J; Turner J; Qiu X; Kobinger GP
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S379-83. PubMed ID: 25957963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective post-exposure treatment of Ebola infection.
    Feldmann H; Jones SM; Daddario-DiCaprio KM; Geisbert JB; Ströher U; Grolla A; Bray M; Fritz EA; Fernando L; Feldmann F; Hensley LE; Geisbert TW
    PLoS Pathog; 2007 Jan; 3(1):e2. PubMed ID: 17238284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge.
    Bukreyev A; Marzi A; Feldmann F; Zhang L; Yang L; Ward JM; Dorward DW; Pickles RJ; Murphy BR; Feldmann H; Collins PL
    Virology; 2009 Jan; 383(2):348-61. PubMed ID: 19010509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus.
    Wong G; Qiu X
    Methods Mol Biol; 2016; 1403():245-57. PubMed ID: 27076134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.